NCT06845592招募中不适用
SHARP - Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- Number of participants free from disease 2 years after HSCT
研究概览
简要总结
The study is a monocentric, interventional study that evaluates the efficacy of allogeneic HLA-matched or haploidentical transplantation consisting of an irradiation-based conditioning regimen coupled with donor Treg/Tcon adoptive immunotherapy for high-risk acute leukemia patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •AML patients
- •Diagnosis of AML with indication to allogeneic hematopoietic cell transplantation.
- •Diagnosis of adverse genetic risk leukemia or presence of MRD or active disease (bone marrow infiltration 5-30%) at the time of the transplant procedure.
- •Availability of a hematopoietic stem cell donor (family or unrelated HLA-matched or HLA-haploidentical with the patient) suitable to be treated with G-CSF (10 mcg/kg/die) for a maximum of 7 days and able to tolerate 2 or more leukaphereses.
- •Age ≥ 18 and ≤ 65 years
- •HCT-CI ≤ 4 (51,52)
- •Absence of relevant psychiatric diseases
- •Signature of the informed consent
- •ALL patients
- •Diagnosis of ALL, either T or B (Philadelphia negative) or mixed phenotype with indication to allogeneic transplant
- •Presence of MRD or active disease (bone marrow infiltration 5-30%) or patient with ≥ 2nd complete hematologic remission at the time of the transplant procedure.
- •Availability of a hematopoietic stem cell family donor (family or unrelated HLA-matched or HLA-haploidentical with the patient) suitable to be treated with G-CSF (10 mcg/kg/die) for a maximum of 7 days and able to tolerate 2 or more leukaphereses.
- •Age ≥ 18 and ≤ 65 years
- •HCT-CI ≤ 4
- •Absence of relevant psychiatric diseases
- •Signature of the informed consent
排除标准
- •AML patients
- •AML in CR MRD-
- •AML with > 5% peripheral blasts or bone marrow infiltration ≥ 30%
- •Age < 18 years or > 65 years
- •ECOG > 2
- •Unacceptable lung, liver, kidney, and/or heart function and presence of relevant psychiatric diseases according to clinical judgment
- •Pregnancy
- •No signature of the informed consent
- •ALL patients
- •ALL with > 5% peripheral blasts or bone marrow infiltration ≥30%
- •Philadelphia positive ALL
- •Age < 18 years or > 65 years
- •ECOG > 2
- •Unacceptable lung, liver, kidney, and/or heart function and presence of relevant psychiatric diseases according to clinical judgment
- •Pregnancy
- •No signature of the informed consent
研究组 & 干预措施
TMLI based contioning and Treg/Tcon adoptive immunotherapy in allogeneic cell transplantation
Experimental
All enrolled patients will receive a 20Gy-TMLI based conditioning regimen followed by the infusion of donor graft and Treg/Tcon adoptive immunotherapy
干预措施: total marrow/lymphoid irradiation (Radiation)
结局指标
主要结局
Number of participants free from disease 2 years after HSCT
时间窗: 2 years
The primary objective of the study is to reduce the incidence of disease relapse after irradiation-based conditioning regimen and Treg/Tcon adoptive immunotherapy-based allogeneic transplantation from HLA-matched or haploidentical donors in high-risk acute leukemia patients.
次要结局
- Number of participants that have reached engraftment 45 days after HSCT(45 days)
- Number of participants that developed grade ≥ 2 acute GvHD(2 years)
- Number of participants free from chronic GvHD 2 years after HSCT(2 years)
研究者
Antonio Pierini
Principal Investigator
University Of Perugia
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
HIFU Treatment of Benign Thyroid NodulesThyroid Nodule (Benign)NCT04233398Theraclion240
招募中
不适用
Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula StenosisArteriovenous Fistula StenosisNCT06422845DK Medical Technology (Suzhou) Co., Ltd.328
进行中（未招募）
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy SubjectsPrevention of Arterial and Venous ThrombosisNCT05369767Beijing Suncadia Pharmaceuticals Co., Ltd64
Unknown
1 期
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ TransplantationAdenovirusCMV InfectionEBVNCT02779439University of Sydney25
进行中（未招募）
1 期
Safety and Tolerability of SHR-1918 in Healthy SubjectsHyperlipemiaNCT05432544Beijing Suncadia Pharmaceuticals Co., Ltd72